ProCE Banner Activity

CE / CME

Expert Guidance on Treatment Advances in Acute Myeloid Leukemia

Multimedia
Watch this interactive webcast of a live CCO webinar to gain expert perspectives on treatment advances for patients with AML

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: February 07, 2022

Expiration: February 06, 2023

No longer available for credit.

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Thomas William LeBlanc

Thomas William LeBlanc, MD, MA, MHS, FAAHPM, FASCO

Associate Professor of Medicine
Associate Professor in Population Health Sciences

Duke University School of Medicine
Duke Cancer Institute
Durham, North Carolina

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Bristol Myers Squibb

Genentech, a member of the Roche Group

Jazz Pharmaceuticals Inc

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients AML.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan evidence-based therapeutic strategies for older patients, those with preexisting comorbidities and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
  • Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Manage treatment-related toxicities associated with novel therapeutics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Amir T. Fathi, MD has disclosed that he has received consulting fees from AbbVie, Agios/Servier, Amgen, Blueprint, Bristol Myers Squibb, Daiichi Sankyo, Foghorn, Forma, Forty Seven, Genentech, Ipsen, Kite, Kura Oncology, Morphosys, New Link Genetics, Novartis, Pfizer, Seattle Genetics, Takeda, Trillium, and Trovagene and funds for research support from AbbVie, Agios/Servier, and Celgene/Bristol Myers Squibb.

Faculty Disclosure

Primary Author

Thomas William LeBlanc, MD, MA, MHS, FAAHPM, FASCO

Associate Professor of Medicine
Associate Professor in Population Health Sciences

Duke University School of Medicine
Duke Cancer Institute
Durham, North Carolina

Thomas LeBlanc MD has disclosed that he has received funds for research support from AstraZeneca, Bristol Myers Squibb/Celgene, Jazz, and Seattle Genetics; consulting fees from AbbVie, Agios/Servier, Amgen, AstraZeneca, Astellas, BlueNote, Bristol Myers Squibb/Celgene, Flatiron, Genentech, and GlaxoSmithKline, Pfizer, and Seagen; and fees for non-CME/CE services from AbbVie, Agios/Servier, and Bristol Myers Squibb/Celgene

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD has disclosed that she has received consulting fees from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and fees for non-CME/CE services from Astellas, Dava Oncology, Jazz, Kura Oncology, Pfizer, and Stemline.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to disclose.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-041-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 07, 2022, through February 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in integrating the most up to date guidelines and expert consensus into the care of their patients with AML.